Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GreeceBack to Greece

Clinical trials in Efkarpia – page 13

680 clinical trials in Efkarpia, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Efkarpia at a glance
680
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

680 trials in Efkarpia

Open in trial search

Immune thrombocytopenia

Recruiting

Study of NVG-2089 given by intravenous infusion in patients with immune thrombocytopenia to evaluate safety and effectiveness

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:NVG-2089
  • Sponsor:Nuvig Therapeutics Inc.

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Nucresiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Major depression

Recruiting

Study of deupsilocin besilate (CYB003) in adults with major depressive disorder comparing two doses against placebo

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Deupsilocin besilate
  • Sponsor:Cybin IRL Limited

Non-small cell lung cancer

Recruiting

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Hormone receptor positive breast cancer+1

Recruiting

Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Varicella

Recruiting

Study of new chickenpox vaccine and measles-mumps-rubella vaccine given by intramuscular injection in healthy children aged 12 to 15 months

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Non-small cell lung cancer stage IV

Recruiting

Study of raludotatug deruxtecan, ifinatamab deruxtecan and docetaxel in patients with previously treated stage IV squamous non-small cell lung cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer+1

Recruiting

Study of ifinatamab deruxtecan, raludotatug deruxtecan and docetaxel in previously treated stage IV non-small cell lung cancer patients

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Autoimmune haemolytic anaemia

Recruiting

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ibuzatrelvir
  • Sponsor:Pfizer Inc.

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Efkarpia

What the registry says about research in the country

01 Dermatology Research

Extensive trials focusing on hidradenitis suppurativa and atopic dermatitis, evaluating novel therapeutic approaches and treatment combinations to improve patient outcomes.

  • Chronic skin conditions
  • Inflammatory disorders
  • Autoimmune skin diseases

Multiple studies testing new biological therapies and their long-term safety profiles.

02 Autoimmune Conditions

Research centered on lupus erythematosus and Sjögren's Disease, investigating targeted therapies to manage disease progression and symptoms.

  • Systemic autoimmune diseases
  • Novel immunological treatments
  • Disease activity markers

Studies aim to evaluate new therapeutic agents for better disease control.

03 Metabolic Disorders

Innovative trials examining treatments for Type 2 Diabetes and obesity, with focus on cardiovascular outcomes and weight management.

  • Diabetes management
  • Weight control therapies
  • Cardiovascular risk reduction

Research comparing new therapeutic options against established treatments.

04 Oncology Studies

Advanced research in metastatic breast cancer and colorectal cancer, evaluating targeted therapies and combination treatments.

  • HER2-positive cancers
  • Treatment resistance
  • Combination therapies

Focus on improving progression-free survival in advanced disease stages.

Back to GreeceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.